

Exhibit 1
MINDRAY MEDICAL INTERNATIONAL LIMITED
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands of US dollars)

	As of December 31, 2013	As of June 30, 2014
	US\$ (Note 1)	US\$ (unaudited)
ASSETS		
Current assets:		
Cash and cash equivalents (Note 2)	385,224	362,311
Restricted cash (Note 3)	759	9,669
Short-term investments (Note 2)	847,041	553,324
Accounts receivable, net	220,228	199,900
Inventories	138,808	158,584
Value added tax receivables	10,225	8,609
Other receivables	21,512	21,132
Prepayments and deposits	14,310	17,909
Deferred tax assets, net	9,585	11,049
Total current assets	1,647,692	1,342,487
Restricted cash, non-current (Note 3)	17,453	10,057
Other assets	10,755	10,821
Accounts receivables, net, non-current	1,389	599
Advances for purchase of plant and equipment	18,919	20,050
Property, plant and equipment, net	324,710	354,039
Land use rights, net	59,463	58,528
Intangible assets, net	181,077	173,417
Goodwill	242,476	253,088
Total assets	2,503,934	2,223,086
LIABILITIES AND EQUITY		
Current liabilities:		
Short-term bank loans	260,000	50,000
Notes payable	10,945	9,391
Accounts payable	93,673	90,580
Advances from customers	28,240	29,312
Salaries payable	91,220	58,512
Other payables and current liabilities	118,951	122,538
Purchase consideration payable	20,457	24,511
Income taxes payable	20,721	15,592
Other taxes payable	12,832	6,155
Total current liabilities	657,039	406,591
Long-term bank loans	215,703	215,393
Other long-term liabilities	7,222	9,290
Deferred tax liabilities, net	45,812	50,646
Total liabilities	925,776	681,920
Shareholders' equity:		
Ordinary shares	15	15
Additional paid-in capital	521,617	442,617
Retained earnings	865,676	902,221
Accumulated other comprehensive income	150,432	134,965
Treasury stock at cost	(18,792)	-
Total shareholders' equity	1,518,948	1,479,818
Non-controlling interests	59,210	61,348
Total equity	1,578,158	1,541,166
Total liabilities and equity	2,503,934	2,223,086

- (1) Financial information is extracted from the audited financial statements included in the Company's 2013 annual report on Form 20-F.
- (2) In respect of cash and cash equivalents and short-term investments, there is an aggregate compensating balance arrangement of \$241,500 and \$189,000 as of December 31, 2013 and June 30, 2014, respectively in relation to the drawings of certain bank loans.
- (3) Restricted cash are mainly those purchase consideration in connection with our acquisitions being held on escrow accounts.

Exhibit 2
MINDRAY MEDICAL INTERNATIONAL LIMITED
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands of US dollars, except share and per share amounts)

	Three months ended June 30,		Six months ended June 30,	
	2013	2014	2013	2014
	US\$	US\$	US\$	US\$
	(unaudited)	(unaudited)	(unaudited)	(unaudited)
Net revenues				
- <i>China</i>	147,415	152,469	258,747	268,297
- <i>International</i>	159,736	181,983	290,507	330,926
Net revenues	307,151	334,452	549,254	599,223
Cost of revenues	(130,668)	(145,237)	(233,706)	(263,988)
Gross profit	176,483	189,215	315,548	335,235
Selling expenses	(54,559)	(63,471)	(101,716)	(118,267)
General and administrative expenses	(26,629)	(27,578)	(53,213)	(57,391)
Research and development expenses	(28,573)	(33,724)	(54,901)	(63,867)
Income from operations	66,722	64,442	105,718	95,710
Other income (expenses), net	421	(215)	499	1,594
Interest income	8,540	7,678	16,227	18,457
Interest expense	(1,471)	(1,291)	(2,443)	(3,686)
Income before income taxes and non-controlling interests	74,212	70,614	120,001	112,075
Income tax (provision) benefits	(10,743)	(9,448)	2,191	(13,948)
Net income	63,469	61,166	122,192	98,127
Less: Net income attributable to non-controlling interests	(1,419)	(1,548)	(2,718)	(2,871)
Net income attributable to the Company	62,050	59,618	119,474	95,256
Basic earnings per share	0.52	0.51	1.01	0.81
Diluted earnings per share	0.51	0.50	0.99	0.81
Shares used in the computation of:				
Basic earnings per share	118,519,629	116,974,009	118,350,730	116,914,653
Diluted earnings per share	120,779,113	118,132,930	120,909,507	118,313,540

Exhibit 3
MINDRAY MEDICAL INTERNATIONAL LIMITED
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands of US dollars)

	Three months ended June 30,		Six months ended June 30,	
	2013	2014	2013	2014
	US\$	US\$	US\$	US\$
	(unaudited)	(unaudited)	(unaudited)	(unaudited)
Cash flow from operating activities:				
Net income	63,469	61,166	122,192	98,127
Adjustments to reconcile net income to net cash provided by operating activities	17,019	20,833	32,329	48,697
Changes in assets and liabilities, net of effects of acquisitions	(4,253)	2,600	(35,896)	(42,559)
Net cash provided by operating activities	76,235	84,599	118,625	104,265
Cash flow from investing activities:				
Acquisition cost of subsidiaries, net of cash received	(13,646)	(6,009)	(17,485)	(8,215)
Capital expenditures	(20,198)	(23,176)	(40,240)	(51,051)
Decrease (Increase) in restricted cash	15,865	4,941	21,264	(1,514)
Proceeds from sale of short-term investments	295,076	374,551	404,337	616,515
Increase in short-term investments and changes in other investing activities	(357,714)	(328,773)	(549,519)	(341,738)
Net cash (used in) provided by investing activities	(80,617)	21,534	(181,643)	213,997
Cash flow from financing activities:				
Repayment of bank loans	(35,000)	(160,000)	(35,000)	(210,000)
Proceeds from bank loans	35,000	-	95,000	-
Dividend paid	-	-	(59,070)	(58,711)
Proceeds from exercise of options	2,098	669	8,852	1,014
Repurchase of ordinary American depositary shares	-	(51)	-	(68,080)
Cash paid to acquire a non-controlling interest	-	(4,286)	-	(4,731)
Cash contribution from a non-controlling interest	-	-	-	239
Net cash provided by (used in) financing activities	2,098	(163,668)	9,782	(340,269)
Net decrease in cash and cash equivalents	(2,284)	(57,535)	(53,236)	(22,007)
Cash and cash equivalents, beginning of period	195,744	419,820	247,859	385,224
Effect of exchange rate changes on cash and cash equivalents	1,913	26	750	(906)
Cash and cash equivalents, end of period	195,373	362,311	195,373	362,311

Exhibit 4
MINDRAY MEDICAL INTERNATIONAL LIMITED
RECONCILIATIONS OF NON-GAAP RESULTS OF OPERATIONS MEASURES TO THE NEAREST COMPARABLE GAAP MEASURES

(In thousands of US dollars, except share and per share amounts)

	Three months ended June 30,		Six months ended June 30,	
	2013	2014	2013	2014
	(unaudited)	(unaudited)	(unaudited)	(unaudited)
	US\$	US\$	US\$	US\$
Non-GAAP net income attributable to the Company	68,238	66,219	132,808	112,273
<i>Non-GAAP net margin</i>	22.2%	19.8%	24.2%	18.7%
Amortization of acquired intangible assets	(3,202)	(3,438)	(5,804)	(6,885)
Deferred tax impact related to acquired intangible assets	209	604	415	1,219
Share-based compensation	(3,195)	(3,767)	(7,945)	(11,351)
GAAP net income attributable to the Company	62,050	59,618	119,474	95,256
<i>GAAP net margin</i>	20.2%	17.8%	21.8%	15.9%
Non-GAAP basic earnings per share	0.58	0.57	1.12	0.96
Non-GAAP diluted earnings per share	0.56	0.56	1.10	0.95
GAAP basic earnings per share	0.52	0.51	1.01	0.81
GAAP diluted earnings per share	0.51	0.50	0.99	0.81
Shares used in computation of:				
Basic earnings per share	118,519,629	116,974,009	118,350,730	116,914,653
Diluted earnings per share	120,779,113	118,132,930	120,909,507	118,313,540
Non-GAAP operating income	73,119	71,647	119,467	113,946
<i>Non-GAAP operating margin</i>	23.8%	21.4%	21.8%	19.0%
Amortization of acquired intangible assets	(3,202)	(3,438)	(5,804)	(6,885)
Share-based compensation	(3,195)	(3,767)	(7,945)	(11,351)
GAAP operating income	66,722	64,442	105,718	95,710
<i>GAAP operating margin</i>	21.7%	19.3%	19.2%	16.0%
Non-GAAP gross profit	178,705	191,414	319,419	339,538
<i>Non-GAAP gross margin</i>	58.2%	57.2%	58.2%	56.7%
Amortization of acquired intangible assets	(2,060)	(1,937)	(3,527)	(3,868)
Share-based compensation	(162)	(262)	(344)	(435)
GAAP gross profit	176,483	189,215	315,548	335,235
<i>GAAP gross margin</i>	57.5%	56.6%	57.5%	55.9%
Non-GAAP selling expenses	(52,191)	(60,585)	(97,097)	(112,759)
<i>Non-GAAP as % of total net revenues</i>	17.0%	18.1%	17.7%	18.8%
Amortization of acquired intangible assets	(1,142)	(1,501)	(2,277)	(3,017)
Share-based compensation	(1,226)	(1,385)	(2,342)	(2,491)
GAAP selling expenses	(54,559)	(63,471)	(101,716)	(118,267)
<i>GAAP as % of total net revenues</i>	17.8%	19.0%	18.5%	19.7%
Non-GAAP general and administrative expenses	(26,023)	(26,844)	(50,181)	(51,406)
<i>Non-GAAP as % of total net revenues</i>	8.5%	8.0%	9.1%	8.6%
Share-based compensation	(606)	(734)	(3,032)	(5,985)
GAAP general and administrative expenses	(26,629)	(27,578)	(53,213)	(57,391)
<i>GAAP as % of total net revenues</i>	8.7%	8.2%	9.7%	9.6%
Non-GAAP research and development expenses	(27,372)	(32,338)	(52,674)	(61,427)
<i>Non-GAAP as % of total net revenues</i>	8.9%	9.7%	9.6%	10.3%
Share-based compensation	(1,201)	(1,386)	(2,227)	(2,440)
GAAP research and development expenses	(28,573)	(33,724)	(54,901)	(63,867)
<i>GAAP as % of total net revenues</i>	9.3%	10.1%	10.0%	10.7%

Exhibit 5**MINDRAY MEDICAL INTERNATIONAL LIMITED****RECONCILIATION OF GAAP NET INCOME TO EARNINGS BEFORE INTEREST, TAXES, DEPRECIATION AND AMORTIZATION****(In thousands of US dollars)**

	Three months ended June 30,		Six months ended June 30,	
	2013	2014	2013	2014
	US\$ (unaudited)	US\$ (unaudited)	US\$ (unaudited)	US\$ (unaudited)
GAAP net income attributable to the Company	62,050	59,618	119,474	95,256
Interest income	(8,540)	(7,678)	(16,227)	(18,457)
Interest expense	1,471	1,291	2,443	3,686
Income tax provision (benefits)	10,743	9,448	(2,191)	13,948
Earnings before interest and taxes ("EBIT")	65,724	62,679	103,499	94,433
Depreciation	7,934	8,704	15,710	17,332
Amortization	5,220	5,567	9,497	11,146
Earnings before interest, taxes, depreciation, and amortization ("EBITDA")	<u>78,878</u>	<u>76,950</u>	<u>128,706</u>	<u>122,911</u>